The Trump administration approved a 2.48% rise in Medicare Advantage payments for 2027, outpacing the roughly flat 2024 proposal.

Analysts had pegged the increase at about 1% or a bullish 2–3%, but the final amount reflects higher projected healthcare costs and a delayed recalibration of enrollee‑health links.

Medicare insurers, including the largest carriers, welcomed the boost, which should support share prices and reassure investors that the agency will adjust policies when technical objections arise.

The decision underscores the agency’s willingness to fine‑tune reimbursement structures to keep plans affordable while protecting insurers’ financial health.